Ireland's infrastructure ‘does not need architects' egos going wild'
The Government is to unveil its revised National Development Plan on Tuesday, which outlines how €200 billion will be spent across various departments over the next 10 years.
Advertisement
The plan, funded by taxpayers' money, some of the €14 billion in Apple tax money and windfalls from sold state shares in AIB, is expected to focus on housing, energy, water and transport infrastructure.
Minister of State Sean Canney said possible US tariffs still pose a major threat to efforts to upgrade Ireland's infrastructure deficit.
The Regional Independent TD, one of the several in the coalition government with Fianna Fáil and Fine Gael, would not indicate what road projects would benefit from the plan, but suggested projects that are 'shovel-ready' would be prioritised.
Mr Canney told RTÉ Radio: 'The first five years, up to 2030, are critical for us.
Advertisement
'We have money in that space to actually get books done and infrastructure put in place – water and sewerage – to allow us to build their housing.'
He added: 'The biggest threat to everything we do, everything we plan, is, of course, the tariffs, where they're going to land.
'I do accept the fact that in all things that we are planning, you have this cloud hanging over us, and nobody can predict what will come from the United States tomorrow or next week or whatever.'
He said he could not outline what specific projects would be funded, but said more road projects would be given 'the go-ahead' in an attempt to spread economic activity across the country.
Advertisement
He said the 'broad figures' for each department would be announced on Tuesday.
'The reason we're doing it that way, it gives departments the flexibility to look at the projects they have coming up, look at which projects are shovel-ready, and we can get them moving as quickly as possible, because in every department, there is an urgency to implement, rather than to be creating more strategies.'
In an apparent reference to the National Children's Hospital, a 'state-of-the-art' public infrastructure project which has been criticised for ballooning to a cost of €2.2 billion, he said there would be an emphasis on functionality.
'It is important that we deliver the projects, but also, and this is a key one, is that we deliver projects which are functional rather than being award-winning, especially in housing and in hospital infrastructure, we need buildings that will function.
Advertisement
'We don't need to see an architect's ego going wild, are we to pay more money for something that's not adding to the functionality?
'I think most people would like to have a home that's comfortable and functional rather than have an award-winning housing estate from an architectural and aesthetic point of view.'
Among the main projects expected to be mentioned in the report is the long-awaited Metrolink, which is estimated to cost at least €9 billion, but the Government has been warned the cost could inflate to €23 billion.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
15 minutes ago
- The Independent
Chancellor faces fiscal risks and ‘significant challenges' amid trade war
The Chancellor could be left at risk of breaking her fiscal rules by unexpected economic shocks and faces 'significant challenges' in delivering the Government's agenda, the International Monetary Fund (IMF) has warned. The IMF said the UK's 'limited' so-called headroom on its public finances gave little room to manoeuvre and called on Rachel Reeves to consider some tax changes or spending cuts. In its annual report on the UK economy, the IMF said: 'Risks to this strategy must be carefully managed. 'In an uncertain global environment and with limited fiscal headroom, fiscal rules could easily be breached if growth disappoints or interest rate shocks materialise.' The IMF praised the Government's fiscal plans, saying they 'strike a good balance between supporting growth and safeguarding fiscal sustainability'. It added that the pro-growth agenda 'covers the right areas to lift productivity'. But the IMF cautioned that 'delivering on this agenda will require overcoming significant challenges' amid the fallout from US President Donald Trump's trade war. 'Shockwaves from trade policies and rapid geopolitical developments are affecting global growth and creating heightened levels of volatility in financial markets,' it said. Added to this, it said, 'fiscal space is limited and constrained by an elevated interest burden and increasing demands on public resources, including defence and aging-related spending'. Ms Reeves said the report 'confirms that the choices we've taken have ensured Britain's economic recovery is under way, and that our plans will tackle the deep-rooted economic challenges that we inherited in the face of global headwinds'. 'Our fiscal rules allow us to confront those challenges by investing in Britain's renewal,' she said. The Washington-based IMF also recommended cutting the number of assessments of whether the Government is on track with its fiscal rules by the Office for Budget Responsibility (OBR) to once a year ahead of the autumn budget. This could 'reduce pressure for overly frequent changes to fiscal policy', it said.
Reuters
16 minutes ago
- Reuters
UK backs future Palestinian statehood but says Gaza ceasefire is priority
LONDON, July 25 (Reuters) - Britain's immediate priority is alleviating suffering in Gaza and securing a ceasefire between Israel and Hamas, a cabinet minister said on Friday, even as Prime Minister Keir Starmer comes under growing pressure to recognise a Palestinian state. Macron announced on Thursday that France would be the first major Western country to recognise a Palestinian state, a plan that drew strong condemnation from Israel and the United States. Starmer will later on Friday discuss ways with other European leaders to pressure Israel to end its war in Gaza. Speaking ahead of that meeting British science and technology minister Peter Kyle told Sky News: "We want Palestinian statehood, we desire it, and we want to make sure the circumstances can exist where that kind of long-term political solution can have the space to evolve." "But right now, today, we've got to focus on what will ease the suffering, and it is extreme, unwarranted suffering in Gaza that has to be the priority for us today." London's Labour Mayor Sadiq Khan, opens new tab and Labour lawmakers on parliament's foreign affairs select committee said this week that Britain should recognise a Palestinian state. A Starmer cabinet minister, Shabana Mahmood, said doing so would bring "multiple benefits" and send a message to Israel. Successive British governments have said they would formally recognise a Palestinian state at the right time, without ever setting a timetable or specifying the conditions for it to happen. Parliament's influential foreign affairs committee said on Friday "the government cannot continue to wait for the perfect time, opens new tab because experience shows that there will never be a perfect time." Starmer was due to hold a call with German and French leaders on Friday over the situation in Gaza, which he described as an "unspeakable and indefensible" humanitarian catastrophe. But in a statement announcing the call, Starmer said while statehood was the "inalienable right of the Palestinian people", Britain would not support it before a ceasefire was agreed. One Labour member of parliament told Reuters that there was unhappiness with Starmer in the party over the government's failure to take more diplomatic steps to condemn Israel. "Most of us are outraged by what is happening in Gaza and think we are being too timid," the lawmaker said. Starmer's approach to the issue was further complicated by the arrival in Scotland later on Friday of U.S. President Donald Trump, with whom he has built warm relations. In foreign policy terms, Britain has rarely diverged from the United States.
Reuters
16 minutes ago
- Reuters
Sarepta fails to win EU backing for muscle disorder gene therapy
July 25 (Reuters) - Sarepta Therapeutics (SRPT.O), opens new tab failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as the company faces intense regulatory scrutiny after two recent patient deaths tied to the treatment. Shares of the Cambridge, Massachusetts-based company slumped 11%. They have lost 88.8% so far this year. The EU committee's negative opinion for Elevidys is yet another major setback for the company, which was directed by the U.S. health regulator earlier this month to stop all shipments of the gene therapy — the only one approved by it for treating Duchenne muscular dystrophy (DMD). Sarepta had already halted dosing in non-ambulatory patients, meaning those unable to walk independently, and later complied with the U.S. Food and Drug Administration's request to pause all shipments, along with Roche (ROG.S), opens new tab — its partner outside the U.S. "While we are disappointed by CHMP's (Committee for Medicinal Products for Human Use) negative opinion, we understand the urgent need for continued dialogue and collaboration to bring transformative therapies to people with Duchenne," said Sarepta's research and development head, Louise Rodino-Klapac. DMD is primarily seen in males, affecting 1 in 5,000 boys born worldwide. The average life expectancy for someone with the disorder is 22 years. William Blair analyst Sami Corwin said the fall in Sarepta shares reflected the reduced revenue from potential future milestone and royalty payments from Roche. "While we believe there is a possibility the pause on Elevidys shipments in the U.S. is lifted before year-end specifically for young and ambulatory patients... the uncertainty will continue to pressure stock." Roche said on Friday it would continue its dialogue with the European Medicines Agency to explore a potential path forward to make Elevidys available in the EU. The benefit-risk profile remains positive in the ambulatory patients, the Swiss drugmaker said. Sarepta said it continues to work with the FDA in the U.S. to address recent safety concerns related to Elevidys.
